Nonalcoholic fatty liver disease in adolescents receiving valproic acid.
Epilepsy Behav
; 20(2): 382-5, 2011 Feb.
Article
en En
| MEDLINE
| ID: mdl-21256090
ABSTRACT
OBJECTIVE:
The aim of this study was to investigate the association between the metabolic derangements induced by valproic acid (VPA) and ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in adolescents.METHODS:
Using a cross-sectional design, we evaluated 86 adolescents with epilepsy who had received VPA monotherapy. Subjects for comparison were 67 normal-weight and 43 weight-matched adolescents. Participants underwent hepatic ultrasound, anthropometric evaluations, and biochemical tests.RESULTS:
Although the occurrence of ultrasound-diagnosed NAFLD was higher in VPA-treated patients than in normal-weight controls (36.0% vs 7.5%, P<0.001), it was similar in VPA-treated patients and weight-matched controls (36.0% vs 34.9%, P>0.05). The identified predictors of NAFLD in VPA-treated patients were abdominal obesity (OR=3.2, 95% CI=2.1-6.8), insulin resistance (OR=2.8, 95% CI=1.7-5.2), metabolic syndrome (OR=2.6, 95% CI=1.4-4.8), and generalized obesity (OR=1.9, 95% CI=1.2-3.7).CONCLUSION:
Valproic acid monotherapy is associated with NAFLD in a high percentage of adolescents with epilepsy who have typical VPA-related metabolic disturbances.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Ácido Valproico
/
Enfermedad Hepática Inducida por Sustancias y Drogas
/
Anticonvulsivantes
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Epilepsy Behav
Asunto de la revista:
CIENCIAS DO COMPORTAMENTO
/
NEUROLOGIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Italia